## FORM 4

Purchase

Common Stock \$ 6.6

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)													
1. Name and Address of Reporting Person *- Yen Yun				LIXT	2. Issuer Name and Ticker or Trading Symbol LIXTE BIOTECHNOLOGY HOLDINGS, INC. [LIXT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director Officer (give title below) Other (specify below)				
(Last) (First) (Middle) 680 E. COLORADO BLVD., SUITE 180					3. Date of Earliest Transaction (Month/Day/Year) 06/30/2022										
(Street) PASADENA, CA 91101				4. If A1	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City		(State)	(Zip)			,	Tabl	e I - Non-Deriv	ative Securitie	es Acquired	, Disposed o	of, or Benef	icially Owned		
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, if any (Month/Day/Year)  2A. Deemed Execution Date, if Code (Instr. 8)  4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  Code V Amount (A) or Price					of (D) Own Tran (Ins	Owned Following Reported Transaction(s) (Instr. 3 and 4) Ownership of Form: Direct (D) or Indirect (I)				. Nature f Indirect Beneficial Ownership Instr. 4)		
Reminder: I	Report on a so	eparate line for each	class of securities b					Persons this form currently	who respond are not requ valid OMB c	ired to res ontrol nur	pond unle nber.			n SEC 14	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g., puts 4. Transaction Code		5. Number of		quired, Disposed of, or Benefits, options, convertible securit  6. Date Exercisable and Expiration Date (Month/Day/Year)				8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Options to Purchase Common Stock	\$ 0.7446	06/30/2022		A		100,000		06/30/2022	06/30/2027	Commor	100,000	\$ 0 (1)	100,000	D	
Options to Purchase Common Stock	\$ 3.03							06/30/2021	06/30/2026	Commor	100,000		100,000	D	
Options to Purchase Common Stock	\$ 3.21							01/06/2021	01/06/2026	Commor	50,000		50,000	D	
Warrants to Purchase Common Stock	\$ 5.7							11/30/2020	11/30/2025	Commor	52,632		52,632	I	By Sino- America Cancer FDD
Options to Purchase Common Stock	\$ 1.68							08/04/2018	08/04/2023	Commor	33,333		33,333	D	
Options															

05/22/2019 05/22/2024 Common

8,333

8,333

D

#### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Yen Yun 680 E. COLORADO BLVD., SUITE 180 PASADENA, CA 91101	X						

#### **Signatures**

/s/ Yun Yen	07/01/2022
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.